On September 11th, Samsung Bioepis, led by CEO Hansung Ko, unveiled a strategic partnership with Switzerland's Sandoz to introduce the biosimilar 'SB17' (active ingredient: Ustekinumab) across North America and Europe.

SB17 marks Samsung Bioepis' fourth biosimilar breakthrough in the realm of immunology, joining the ranks of 'SB4 (Enbrel biosimilar)', 'SB2 (Remicade biosimilar)', and 'SB5 (Humira biosimilar)'. The company proudly reveals a track record of supplying over 48 million autoimmune disease treatments to nearly 40 countries across the globe, spanning more than five years.

In March, Samsung Bioepis presented the outcomes of the phase 1 clinical trial of SB17 at the annual meeting of the American Academy of Dermatology (AAD) in the United States, affirming its equivalence in pharmacokinetics (PK), safety, and immunogenicity when compared to the original drug. The phase 3 clinical trial of SB17 concluded in December 2022, and Samsung Bioepis intends to unveil the results at an upcoming academic conference later this year.

Sang-Jin Pak, Executive Vice President and Head of the Commercial Division, remarked, "This partnership underscores our unwavering commitment to the autoimmune disease treatment market." He further noted, "It reinforces the value of expanding patient accessibility through biosimilars."